Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis
Inflammatory bowel disease (IBD) is commonly associated with peripheral inflammatory arthritis, and it has been estimated that as many as 12% of IBD patients report these manifestations. However, rheumatoid arthritis (RA) is rarely associated with ulcerative colitis (UC). Among all the biological ag...
Main Authors: | G. Andrisani, E. Gremese, L. Guidi, A. Papa, M. Marzo, C. Felice, D. Pugliese, A. Armuzzi |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2013-05-01
|
Series: | Reumatismo |
Subjects: | |
Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/648 |
Similar Items
-
Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis
by: Sebastian Hoffmann, et al.
Published: (2018-05-01) -
Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis
by: Laurel L. Wessman, BS, et al.
Published: (2017-07-01) -
Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
by: Vandana Midha, et al.
Published: (2018-01-01) -
Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up
by: Chandra A, et al.
Published: (2019-11-01) -
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
by: Pugliese D, et al.
Published: (2016-02-01)